ArticleMolecular cancer2015
A molecular signature for the prediction of recurrence in colorectal cancer.
Article in Molecular cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Poliovirus receptor (PVR) expression as a predictor of relapse in colorectal cancer: bioinformatics and virtual screening.Experimental biology and medicine (Maywood, N.J.) · 2026Article
- Transcriptome-Based Traits of Radioresistant Sublines of Non-Small Cell Lung Cancer Cells.International journal of molecular sciences · 2023Article
- A novel 9-gene signature for the prediction of postoperative recurrence in stage II/III colorectal cancer.Frontiers in genetics · 2022Article
- Pathological Characteristics, Prognostic Determinants and the Outcome of Patients Diagnosed with Colorectal Adenocarcinoma at the University Teaching Hospital of Kigali.Canadian journal of gastroenterology & hepatology · 2022Article
- Review
- TNNT2 as a potential biomarker for the progression and prognosis of colorectal cancer.Oncology reports · 2020Article
- A network-based predictive gene expression signature for recurrence risks in stage II colorectal cancer.Cancer medicine · 2020Article
- BRIP-1 germline mutation and its role in colon cancer: presentation of two case reports and review of literature.BMC medical genetics · 2019Review
- Batch adjustment by reference alignment (BARA): Improved prediction performance in biological test sets with batch effects.PloS one · 2019Article
- Recurrence-Associated Long Non-coding RNA Signature for Determining the Risk of Recurrence in Patients with Colon Cancer.Molecular therapy. Nucleic acids · 2018Article
- Identification of key lncRNAs in colorectal cancer progression based on associated protein-protein interaction analysis.World journal of surgical oncology · 2017Article
- Gene signatures associated with drug resistance to irinotecan and oxaliplatin predict a poor prognosis in patients with colorectal cancer.Oncology letters · 2017Article
- Integrated Analysis Identifies Molecular Signatures and Specific Prognostic Factors for Different Gastric Cancer Subtypes.Translational oncology · 2017Article
- Pan-organ transcriptome variation across 21 cancer types.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral clinical and pathological factors have an impact on the prognosis of colorectal cancer (CRC), but they are not yet adequate for risk assessment. We aimed to identify a molecular signature that can reliably identify CRC patients at high risk for recurrence.
resultsTwo hundred eighty-one CRC samples (stage II/III) were included in this study. A two-step gene expression profiling study was conducted. First, gene expression measurements from 81 fresh frozen CRC samples were obtained using Affymetrix Human Genome U133 Plus 2.0 Arrays. Second, a focused gene expression assay, including prognostic genes and genes of interest from literature reviews, was performed using 200 fresh frozen samples and a Taqman low-density array (TLDA) analysis. An optimal 31-gene expression classifier for the prediction of recurrence among patients with stage II/III CRC was developed using logistic regression analysis. This gene expression signature classified 58.5% of patients as low-risk and 41.5% as high-risk (P < 0.001). The signature was the strongest independent prognostic factor in the multivariate analysis. The five-year relapse-free survival (RFS) rates for the low-risk patients and the high-risk patients were 88.5% and 41.3% (P < 0.001), respectively.
conclusionWe identified a 31-gene expression signature that is closely associated with the clinical outcome of stage II/III CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.